Incorporation of Ursolic Acid in Liquid Crystalline Systems Improves the Antifungal Activity Against Candida Sp

Detalhes bibliográficos
Autor(a) principal: Marena, Gabriel Davi [UNESP]
Data de Publicação: 2020
Outros Autores: Fonseca-Santos, Bruno [UNESP], Matheus Aparecido dos Santos, Ramos [UNESP], dos Santos, Karen Cristina [UNESP], Bauab, Taís Maria [UNESP], Chorilli, Marlus [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1007/s12247-020-09470-0
http://hdl.handle.net/11449/201944
Resumo: Purpose: Infectious diseases caused by Candida sp. have high drug resistance due to the uncontrolled use of antibiotics. Among the natural products, ursolic acid (UA), a triterpene, has been increasing interest due to its antimicrobial effects. However, the physicochemical properties of UA, such as its low aqueous solubility, lead to failure of therapeutic application. Because of this, drug release systems, such as liquid crystals (LCs), can improve solubilization and increase the therapeutic efficacy of many drugs. Methods: In this work, we evaluated the antifungal potential of UA and loaded into LC precursor system against Candida sp. The system was composed of oleic acid (30%), polysorbate 80 (60%), and purified water (10%). Polarized light microscopy, rheological assays, and simulated vaginal fluid (SVF) simulations were performed. Cytotoxicity assay was evaluated against L-929 cells (murine fibroblast), and antifungal evaluation was performed by microplate microdilution method against Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, and Candida tropicalis. Results: The system showed acceptable parameters for UA incorporation, such as adhesiveness, texture, and flow behaviors, compatible to vaginal administration. Free UA showed no antifungal activity; however, after incorporation into LCs, it was observed against C. albicans, C. glabrata, C. tropicalis, and C. parapsilosis (MIC values around 500 μg/mL and 3.9 μg/cell viability assays showed moderate cytotoxicity [halo diameter 1.00 ± 0.156]). Conclusion: In conclusion, the results corroborate in the materials field as a possible alternative in the treatment of infectious diseases by Candida species and the systems showed potential promising for enhancing AU antifungal performance with the application on vulvovaginitis.
id UNSP_f846b7e2ee8a4b761b810a866360cb78
oai_identifier_str oai:repositorio.unesp.br:11449/201944
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Incorporation of Ursolic Acid in Liquid Crystalline Systems Improves the Antifungal Activity Against Candida SpCandida speciesFungal infectionsLiquid crystal systemNanotechnologyUrsolic acidPurpose: Infectious diseases caused by Candida sp. have high drug resistance due to the uncontrolled use of antibiotics. Among the natural products, ursolic acid (UA), a triterpene, has been increasing interest due to its antimicrobial effects. However, the physicochemical properties of UA, such as its low aqueous solubility, lead to failure of therapeutic application. Because of this, drug release systems, such as liquid crystals (LCs), can improve solubilization and increase the therapeutic efficacy of many drugs. Methods: In this work, we evaluated the antifungal potential of UA and loaded into LC precursor system against Candida sp. The system was composed of oleic acid (30%), polysorbate 80 (60%), and purified water (10%). Polarized light microscopy, rheological assays, and simulated vaginal fluid (SVF) simulations were performed. Cytotoxicity assay was evaluated against L-929 cells (murine fibroblast), and antifungal evaluation was performed by microplate microdilution method against Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, and Candida tropicalis. Results: The system showed acceptable parameters for UA incorporation, such as adhesiveness, texture, and flow behaviors, compatible to vaginal administration. Free UA showed no antifungal activity; however, after incorporation into LCs, it was observed against C. albicans, C. glabrata, C. tropicalis, and C. parapsilosis (MIC values around 500 μg/mL and 3.9 μg/cell viability assays showed moderate cytotoxicity [halo diameter 1.00 ± 0.156]). Conclusion: In conclusion, the results corroborate in the materials field as a possible alternative in the treatment of infectious diseases by Candida species and the systems showed potential promising for enhancing AU antifungal performance with the application on vulvovaginitis.School of Pharmaceutical Sciences São Paulo State University (UNESP)School of Pharmaceutical Sciences São Paulo State University (UNESP)Universidade Estadual Paulista (Unesp)Marena, Gabriel Davi [UNESP]Fonseca-Santos, Bruno [UNESP]Matheus Aparecido dos Santos, Ramos [UNESP]dos Santos, Karen Cristina [UNESP]Bauab, Taís Maria [UNESP]Chorilli, Marlus [UNESP]2020-12-12T02:45:55Z2020-12-12T02:45:55Z2020-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1007/s12247-020-09470-0Journal of Pharmaceutical Innovation.1939-80421872-5120http://hdl.handle.net/11449/20194410.1007/s12247-020-09470-02-s2.0-85087709529Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengJournal of Pharmaceutical Innovationinfo:eu-repo/semantics/openAccess2024-06-24T13:46:24Zoai:repositorio.unesp.br:11449/201944Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T22:37:03.789817Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Incorporation of Ursolic Acid in Liquid Crystalline Systems Improves the Antifungal Activity Against Candida Sp
title Incorporation of Ursolic Acid in Liquid Crystalline Systems Improves the Antifungal Activity Against Candida Sp
spellingShingle Incorporation of Ursolic Acid in Liquid Crystalline Systems Improves the Antifungal Activity Against Candida Sp
Marena, Gabriel Davi [UNESP]
Candida species
Fungal infections
Liquid crystal system
Nanotechnology
Ursolic acid
title_short Incorporation of Ursolic Acid in Liquid Crystalline Systems Improves the Antifungal Activity Against Candida Sp
title_full Incorporation of Ursolic Acid in Liquid Crystalline Systems Improves the Antifungal Activity Against Candida Sp
title_fullStr Incorporation of Ursolic Acid in Liquid Crystalline Systems Improves the Antifungal Activity Against Candida Sp
title_full_unstemmed Incorporation of Ursolic Acid in Liquid Crystalline Systems Improves the Antifungal Activity Against Candida Sp
title_sort Incorporation of Ursolic Acid in Liquid Crystalline Systems Improves the Antifungal Activity Against Candida Sp
author Marena, Gabriel Davi [UNESP]
author_facet Marena, Gabriel Davi [UNESP]
Fonseca-Santos, Bruno [UNESP]
Matheus Aparecido dos Santos, Ramos [UNESP]
dos Santos, Karen Cristina [UNESP]
Bauab, Taís Maria [UNESP]
Chorilli, Marlus [UNESP]
author_role author
author2 Fonseca-Santos, Bruno [UNESP]
Matheus Aparecido dos Santos, Ramos [UNESP]
dos Santos, Karen Cristina [UNESP]
Bauab, Taís Maria [UNESP]
Chorilli, Marlus [UNESP]
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (Unesp)
dc.contributor.author.fl_str_mv Marena, Gabriel Davi [UNESP]
Fonseca-Santos, Bruno [UNESP]
Matheus Aparecido dos Santos, Ramos [UNESP]
dos Santos, Karen Cristina [UNESP]
Bauab, Taís Maria [UNESP]
Chorilli, Marlus [UNESP]
dc.subject.por.fl_str_mv Candida species
Fungal infections
Liquid crystal system
Nanotechnology
Ursolic acid
topic Candida species
Fungal infections
Liquid crystal system
Nanotechnology
Ursolic acid
description Purpose: Infectious diseases caused by Candida sp. have high drug resistance due to the uncontrolled use of antibiotics. Among the natural products, ursolic acid (UA), a triterpene, has been increasing interest due to its antimicrobial effects. However, the physicochemical properties of UA, such as its low aqueous solubility, lead to failure of therapeutic application. Because of this, drug release systems, such as liquid crystals (LCs), can improve solubilization and increase the therapeutic efficacy of many drugs. Methods: In this work, we evaluated the antifungal potential of UA and loaded into LC precursor system against Candida sp. The system was composed of oleic acid (30%), polysorbate 80 (60%), and purified water (10%). Polarized light microscopy, rheological assays, and simulated vaginal fluid (SVF) simulations were performed. Cytotoxicity assay was evaluated against L-929 cells (murine fibroblast), and antifungal evaluation was performed by microplate microdilution method against Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, and Candida tropicalis. Results: The system showed acceptable parameters for UA incorporation, such as adhesiveness, texture, and flow behaviors, compatible to vaginal administration. Free UA showed no antifungal activity; however, after incorporation into LCs, it was observed against C. albicans, C. glabrata, C. tropicalis, and C. parapsilosis (MIC values around 500 μg/mL and 3.9 μg/cell viability assays showed moderate cytotoxicity [halo diameter 1.00 ± 0.156]). Conclusion: In conclusion, the results corroborate in the materials field as a possible alternative in the treatment of infectious diseases by Candida species and the systems showed potential promising for enhancing AU antifungal performance with the application on vulvovaginitis.
publishDate 2020
dc.date.none.fl_str_mv 2020-12-12T02:45:55Z
2020-12-12T02:45:55Z
2020-01-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1007/s12247-020-09470-0
Journal of Pharmaceutical Innovation.
1939-8042
1872-5120
http://hdl.handle.net/11449/201944
10.1007/s12247-020-09470-0
2-s2.0-85087709529
url http://dx.doi.org/10.1007/s12247-020-09470-0
http://hdl.handle.net/11449/201944
identifier_str_mv Journal of Pharmaceutical Innovation.
1939-8042
1872-5120
10.1007/s12247-020-09470-0
2-s2.0-85087709529
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Journal of Pharmaceutical Innovation
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808129443390029824